Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 5/20 | 0.46 |
| ▸ | THRB | P10828 | 5/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6125199 | 0.89 | PTPN1 (0.47) | PTPN1HPGDLMNAMAOBFFAR4 | |
| SCHEMBL9279822 | 0.89 | PTPN1 (0.44) | PTPN1HPGDLMNAMAOBFFAR4 | |
| SCHEMBL113286 | 0.86 | PTPN1 (0.42) | PTPN1SMN1; SMN2HPGDLMNAMAOB | |
| SCHEMBL9283029 | 0.86 | KDM4E (0.46) | THRATHRBPTPN1HPGDLMNA | |
| SCHEMBL11908734 | 0.85 | MEN1 (0.47) | THRATHRBPTPN1SMN1; SMN2HPGD | |
| SCHEMBL6128425 | 0.85 | THRB (0.44) | THRATHRBLMNAMAPT | |
| SCHEMBL19035748 | 0.84 | LMNA (0.43) | PTPN1SMN1; SMN2HPGDLMNAMAOB | |
| SCHEMBL113438 | 0.82 | TSPO (0.41) | PTPN1HPGDLMNAMAOBFFAR4 | |
| SCHEMBL114286 | 0.82 | PTGES (0.45) | PTPN1HPGDLMNAMAPT | |
| SCHEMBL14125036 | 0.81 | PTGER4 (0.39) | PTPN1HPGDLMNAMAOBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| EP-3461809-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2019-04-03 | — | — | EP | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170305852-A1 | Tetracyline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| EP-3000805-B1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-8501716-B2 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120135968-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2424834-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | President and Fellows of Harvard College (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TET1, TET3, TYMS | THRA 637/4885THRB 1009/4885PTPN1 2298/4885 |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
| US-20170305852-A1 | Tetracyline Compounds | SLC10A1, CYP3A7, TAAR5 | THRA 831/4885THRB 569/4885PTPN1 824/4885 |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
| US-20120302527-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | THRA 791/4885THRB 1053/4885PTPN1 470/4885 |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
| US-20120135968-A1 | Tetracycline Compounds | TUBB, TUBA1C, TUBA1A | THRA 256/4885THRB 395/4885PTPN1 402/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | THRA 256/4885THRB 395/4885PTPN1 402/4885 |
| US-20130109657-A1 | C7-Fluoro Substituted Tetracycline Compounds | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | THRA 753/4885THRB 1229/4885PTPN1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.